11 May 2026
11 May 2026
The leased facility will manufacture diagnostic instruments, equipment, and consumables.
Preliminary insights from the Phase III trial are anticipated to be available in 2027.
The approval was based on results from the POETYK PsA-I and POETYK PsA-II Phase III clinical trials.
Microsure will generate clinical data at European sites and evaluate MUSA-3 in super-microsurgery.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
